Transaction overview

REGENXBIO Inc., a gene therapy company based in Rockville, Maryland, entered into a non-dilutive royalty bond agreement on May 19, 2025, securing $150 million from Healthcare Royalty (HCRx) to monetize anticipated royalties and milestones. The deal extends REGENXBIO's cash runway into early 2027, providing crucial funding for its late-stage gene therapy programs.

Deal structure and financing

The agreement involves a non-dilutive royalty bond of up to $250 million, with HCRx receiving quarterly interest payments derived solely from the revenue generated by REGENXBIO's royalties and milestone payments. These include revenues from ZOLGENSMA for spinal muscular atrophy (SMA) and milestones from RGX-121 and RGX-111 for MPS II and I, among others. HCRx also received warrants to purchase up to 268,096 shares of REGENXBIO's common stock at an exercise price of $14.92, which is a 100% premium over the company’s 30-day weighted average share price. An additional $50 million will be disbursed by April 30, 2027, contingent on ZOLGENSMA sales milestones, and another $50 million upon mutual agreement between both parties.

Strategic context

REGENXBIO sought this arrangement to monetize its anticipated future revenue streams without issuing additional equity, thereby preserving shareholder value. This approach also aligns with the company's strategy of leveraging non-dilutive capital structures to advance its pipeline of gene therapies for rare and retinal diseases. The financing will support REGENXBIO’s commercial preparations and extend its cash runway beyond key milestones such as potential FDA approval of RGX-121 for MPS II, BLA submission for RGX-202 for Duchenne muscular dystrophy, and pivotal studies for subretinal ABBV-RGX-314 in wet age-related macular degeneration (AMD). Healthcare Royalty, on the other hand, gains exposure to REGENXBIO’s diversified royalty-generating portfolio, which aligns with its investment strategy focusing on commercial or near-commercial biopharmaceutical products.

Regulatory path

The transaction did not require regulatory approval due to its non-equity financing nature. The agreement involves internal corporate structuring and does not involve antitrust concerns or cross-jurisdictional issues that would necessitate filings with the Federal Trade Commission (FTC) or European Union regulators. Therefore, no formal regulatory review was needed for this financial arrangement between REGENXBIO and Healthcare Royalty.